These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 16444864

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
    Maas R.
    Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
    [Abstract] [Full Text] [Related]

  • 3. ADMA and hyperhomocysteinemia.
    Dayal S, Lentz SR.
    Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
    [Abstract] [Full Text] [Related]

  • 4. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
    Sydow K, Mondon CE, Cooke JP.
    Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The biology and therapeutic potential of the DDAH/ADMA pathway.
    Arrigoni F, Ahmetaj B, Leiper J.
    Curr Pharm Des; 2010 Jul; 16(37):4089-102. PubMed ID: 21247398
    [Abstract] [Full Text] [Related]

  • 11. The clinical significance of asymmetric dimethylarginine.
    Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA.
    Annu Rev Nutr; 2006 Jul; 26():203-28. PubMed ID: 16848705
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
    Weis M, Kledal TN, Lin KY, Panchal SN, Gao SZ, Valantine HA, Mocarski ES, Cooke JP.
    Circulation; 2004 Feb 03; 109(4):500-5. PubMed ID: 14732750
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The DDAH-ADMA-NOS pathway.
    Leiper JM.
    Ther Drug Monit; 2005 Dec 03; 27(6):744-6. PubMed ID: 16404814
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
    Toutouzas K, Riga M, Stefanadi E, Stefanadis C.
    Horm Metab Res; 2008 Sep 03; 40(9):655-9. PubMed ID: 18792879
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.